Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $39,621.45 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction on Friday, April 12th. The stock was sold at an average price of $20.35, for a total transaction of $39,621.45. Following the transaction, the insider now owns 65,418 shares in the company, valued at approximately $1,331,256.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Castle Biosciences Stock Performance

CSTL opened at $19.20 on Friday. The stock has a market cap of $527.04 million, a price-to-earnings ratio of -8.89 and a beta of 0.93. The firm’s fifty day moving average is $21.62 and its 200 day moving average is $19.82. Castle Biosciences, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.74. The business had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. On average, equities research analysts predict that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Analysts Set New Price Targets

CSTL has been the topic of several analyst reports. KeyCorp lifted their target price on Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Scotiabank lifted their price objective on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research report on Friday, March 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. BluePath Capital Management LLC bought a new stake in shares of Castle Biosciences during the third quarter valued at approximately $31,000. Royal Bank of Canada lifted its stake in Castle Biosciences by 40.5% in the 2nd quarter. Royal Bank of Canada now owns 2,880 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares in the last quarter. O Dell Group LLC bought a new position in shares of Castle Biosciences during the 4th quarter valued at about $44,000. Tower Research Capital LLC TRC boosted its holdings in shares of Castle Biosciences by 61.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after purchasing an additional 691 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in shares of Castle Biosciences by 37.2% in the second quarter. Osaic Holdings Inc. now owns 3,626 shares of the company’s stock worth $50,000 after purchasing an additional 984 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.